Weight-loss medications like Wegovy are driving a significant shift in clinical nutrition, as thousands of patients report life-altering physical changes despite persistent social stigma and high out-of-pocket costs. According to Health NZ data from May, 35,961 patients in New Zealand are currently using GLP-1 receptor agonists to manage weight, navigating a complex landscape of financial burden and evolving dietary requirements.
The Cost of Clinical Weight Management
For many patients, the financial commitment required to maintain a GLP-1 regimen is substantial. Valentina Florez-Betancur, a 26-year-old Wellington resident, reports spending approximately $469 every four weeks for the highest dosage of Wegovy. Because the drug is not publicly funded in New Zealand, Florez-Betancur often relies on payment installments, such as Afterpay, to secure her monthly prescription.
Despite the financial strain, Florez-Betancur describes the investment as necessary. After gaining weight during a period of depression—moving from 60kg to 83kg in two years—she sought the medication to mitigate risks of diabetes and to increase her chances of a healthy future pregnancy. After six months of use, she has lost 16kg, noting that the physical and psychological benefits outweigh the significant “dent in her pocket.”
Did you know?
While many assume GLP-1 users undergo a complete lifestyle overhaul, patients like Florez-Betancur report that their food preferences often remain consistent. The medication primarily functions by altering hunger signals rather than mandating a specific “health-freak” diet.
Shifting Nutritional Priorities
The rise of GLP-1 medications has forced a change in how dietitians approach weight loss. Kylie Russel, a dietitian, notes that the clinical focus has moved away from traditional calorie restriction. Instead, practitioners are now tasked with ensuring patients consume adequate nutrients while their appetite is suppressed.
“Historically, working with someone to lose weight has always been about ‘how do I get this person to eat less?'” Russel says. “But now my job is about ‘how do I get this person to eat enough of these key foods to ensure overall nutrition adequacy?'”
Russel identifies protein, fiber, and vitamin D as critical areas of concern. She emphasizes that while the risk of nutritional deficiency is a real challenge in her field, it remains entirely preventable with proper professional support and patient education.
Addressing the Social Stigma
Despite the growing number of users, many patients report that the stigma surrounding weight-loss medication prevents open discussion. Florez-Betancur, who is part of a 15,000-member Facebook group for GLP-1 users, notes that many participants choose to remain anonymous due to public judgment.
This “damned if you do, damned if you don’t” sentiment reflects a dual challenge: individuals are often judged for being overweight, yet face further scrutiny when utilizing medical interventions to address it. For patients like Florez-Betancur, the solution is to prioritize personal health outcomes over external perceptions.
Frequently Asked Questions
Are GLP-1 drugs like Wegovy publicly funded in New Zealand?
No, currently these medications are not funded, leading to significant out-of-pocket expenses for patients.
Do I have to change my diet completely on Wegovy?
Not necessarily. While dietitians emphasize the need for protein, fiber, and vitamin D, patients report that their underlying food preferences do not always change drastically.
What is the biggest challenge for dietitians with GLP-1 patients?
Dietitians are shifting their focus from calorie restriction to ensuring patients eat enough nutrient-dense food to avoid deficiencies.
Have you or someone you know navigated the transition to GLP-1 medications? Share your experience in the comments below or subscribe to our newsletter for more updates on emerging health trends.